Tilray Stock 18.46% Up Before The Weekend

(VIANEWS) – The NASDAQ ended the session with Tilray (TLRY) rising 18.46% to $2.31 on Friday while NASDAQ rose 0.16% to $16,428.82.

Tilray’s last close was $1.95, 42.65% below its 52-week high of $3.40.

About Tilray

Tilray Brands, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It also offers medical and adult-use cannabis products; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. In addition, the company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.

Earnings Per Share

As for profitability, Tilray has a trailing twelve months EPS of $-2.28.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -36%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 34.4%, now sitting on 700.5M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Tilray’s stock is considered to be oversold (<=20).

Earnings Before Interest, Taxes, Depreciation, and Amortization

Tilray’s EBITDA is -151.76.

Sales Growth

Tilray’s sales growth for the next quarter is 26.1%.

More news about Tilray (TLRY).

Leave a Reply

Your email address will not be published. Required fields are marked *